We do not know whether a second round of treatment with palbociclib would have been more efficacious in these sarcomas because all of them appeared to respond to the first round of treatment; however, in some samples (S29), we did not observe a clear decrease in the expression of the proliferation marker KI67 (Figure 5). Here, MKI67 is linked to sarcoma.